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Schizophrenia is a severe psychiatric disorder that 
has a worldwide prevalence of 0.5%[1] and poses a 
high cost to society.[2] The disorder is characterized 
by positive symptoms, such as hallucinations and 
delusions,[3] negative symptoms, such as impaired 
emotional functioning and behavioral disruptions (e.g. 
flat affect, difficulty in starting activities and completing 
them, etc.),[4] and cognitive symptoms, such as deficits 
in executive functioning, impaired working memory, 
and attention problems.[5] Less known to the general 
public is the fact that a large number of the patients 
with schizophrenia suffer from sleep disturbances, 
such as reduced sleep efficiency, reduced total sleep 
time, and increased sleep latency.[6] Surprisingly, those 
sleep problems in patients with schizophrenia are also 
often under-estimated in daily clinical practice.[7]
In the Diagnostic and Statistical Manual of Mental 
Disorders 5th Edition (DSM-V),[8] sleep-wake disorders 
are classified into 10 disorders or disorder groups (e.g. 
insomnia disorder, restless legs syndrome, circadian 
rhythm sleep-wake disorders, etc.). Patients suffering 
from sleep-wake disorders have problems with respect 
to the quality, the timing, and the total amount of sleep,[8] 
leading to distress and impairment in their social and 
cognitive functioning.[9]
Several treatments have been used in patients with 
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schizophrenia, as well as patients with sleep-wake 
disorders. Pharmacological treatment with first- and 
second-generation antipsychotics (e.g. amisulpride, 
clozapine, olanzapine, risperidone, etc.) is still the 
most frequently used treatment in patients with first-
episode and long-term schizophrenia.[10] However, 
mainly because of the adverse effects of the 
pharmacological treatment, non-pharmacological add-
on treatments, such as cognitive behavioral therapy,[11] 
are being increasingly used. Sleep-wake disorders 
are mostly treated with pharmacological interventions, 
such as benzodiazepines, zolpidem, zaleplon, etc., but 
unfortunately, side-effects are common here, as well.[12] 
In addition, non-pharmacological interventions, such 
as cognitive psychotherapy, sleep hygiene, relaxation 
therapy, acupuncture, etc.,[13,14] are used.
Previous research involving patients with 
schizophrenia and comorbid sleep disorders has 
shown that a relation exists between sleep problems 
and cognitive functioning.[15] For instance, in a recent 
study, a significant negative relationship was found 
between the number of sleep problems and the 
working memory performance; i.e. the more severe the 
patient’s sleep problems was, the lower the patient’s 
working memory performance was.[15] However, more 
research is warranted, and to date, many questions 
remain unanswered: Firstly, how are poor sleep 
and decreased social and cognitive functioning in 
patients with schizophrenia related? Secondly, what 
role does the pharmacological treatment of patients 
with schizophrenia play in their impaired sleep and 
social and cognitive functioning? For instance, 
benzodiazepines are known to suppress rapid-eye-
movement (REM) sleep,[12] and when patients stop 
such medications, episodes of increased REM sleep 
are more numerous.[12] Because REM sleep plays 
a role in the learning process, as well as in memory 
consolidation,[12] future research should clarify whether 
benzodiazepines might have a negative influence on 
cognitive functioning, e.g. working memory, in patients 
with schizophrenia and comorbid sleep disorders. 
Thirdly, how does the pharmacological treatment of 
comorbid sleep disorders in patients with schizophrenia 
interfere with the pharmacological treatment of the 
positive and the negative symptoms of those patients? 
These questions need to be investigated and answered 
in future studies so as to improve further the treatment 
and the quality of life of patients with schizophrenia 
and comorbid sleep disorders.
Here, an important finding is that in previous research, 
patients with schizophrenia tended to underestimate 
their problems on self-report inventories.[16] 
Therefore, in future research, both “objective” (e.g. 
electroencephalography, actiwatches, etc.) and 
“subjective” (e.g. self-report inventories, such as the 
Pittsburgh Sleep Quality Index,[17] Munich Parasomnia 
Screening,[18] etc.) measurements must be used 
if the efficiencies of various pharmacological and 
non-pharmacological treatments of patients with 
schizophrenia and comorbid sleep disorders are to be 
determined with accuracy.
To conclude, many patients with schizophrenia suffer 
from comorbid sleep-wake disorders. Therefore, in 
daily clinical practice, sleep needs more attention in 
the treatment of patients with schizophrenia so that 
such patients receive optimal treatment and their 
qualities of life are increased. Finally, evidence for 
adding “disturbed sleep” as one of the characteristic 
symptoms of schizophrenia in the DSM system seems 
to be mounting.[8,15]
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